International Journal of Endocrinology

International Journal of Endocrinology / 2014 / Article

Erratum | Open Access

Volume 2014 |Article ID 302602 | 1 page | https://doi.org/10.1155/2014/302602

Erratum to “Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)”

Received05 Mar 2014
Accepted16 Apr 2014
Published27 Apr 2014

In the paper, the dosage of telmisartan is incorrect due to a typographical error. Twelve patients, assigned to telmisartan group, received telmisartan at a dose of 40 mg, not 20 mg, once a day. The correct sentences should appear as given below.(1)“Nineteen hypertensive NAFLD patients with type 2 diabetes were randomly assigned to receive telmisartan at a dose of 40 mg once a day () or losartan at a dose of 50 mg once a day () for 12 months” in the “Methods” section of the “Abstract.”(2)“Nineteen hypertensive NAFLD patients with type 2 diabetes were randomly assigned to the telmisartan (T) group (receiving a standard dose of 40 mg once daily, ) or the losartan (L) group (receiving a standard dose of 50 mg once daily, )” in Section 2.2.

Copyright © 2014 Takumi Hirata et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

1024 Views | 558 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.